Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia

NCT05419050 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

NIH

Sponsor class

Conditions

Fibrous Dysplasia

Interventions

DRUG: denosumab

Sponsor

National Institute of Dental and Craniofacial Research (NIDCR)